Shopping Cart 0
Cart Subtotal
USD 0

Granulomatosis with Polyangiitis (Wegeners Granulomatosis) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis-Pipeline Review, H2 2018, provides an overview of the Granulomatosis with Polyangiitis (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1, 1, 1 and 3 respectively.

Granulomatosis with Polyangiitis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Immunology).

- The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Granulomatosis with Polyangiitis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Overview

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Celltrion Inc

ChemoCentryx Inc

Humanigen Inc

Kyowa Hakko Kirin Co Ltd

Nichi-Iko Pharmaceutical Co Ltd

Sandoz International GmbH

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Drug Profiles

abatacept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacopan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HGEN-005-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Dormant Projects

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Discontinued Products

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Product Development Milestones

Featured News & Press Releases

Jun 29, 2017: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan (rituximab)

May 18, 2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab)

Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Pipeline by Bristol-Myers Squibb Co, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Pipeline by Celltrion Inc, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Pipeline by ChemoCentryx Inc, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Pipeline by Humanigen Inc, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Pipeline by Sandoz International GmbH, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Dormant Projects, H2 2018

Granulomatosis with Polyangiitis (Wegener's Granulomatosis)-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Granulomatosis with Polyangiitis (Wegener Polyangiitis) Therapeutic Products under Development, Key Players in Granulomatosis with Polyangiitis (Wegener Polyangiitis) Therapeutics, Granulomatosis with Polyangiitis (Wegener Polyangiitis) Pipeline Overview, Granulomatosis with Polyangiitis (Wegener Polyangiitis) Pipeline, Granulomatosis with Polyangiitis (Wegener Polyangiitis) Pipeline Assessment


Companies

Bristol-Myers Squibb Co

Celltrion Inc

ChemoCentryx Inc

Humanigen Inc

Kyowa Hakko Kirin Co Ltd

Nichi-Iko Pharmaceutical Co Ltd

Sandoz International GmbH